BioSpace News Archive

Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it has been granted Fast Track designation by the FDA for RBT-9 treatment in COVID-19.

TrueLimb Is an Ultralight, Comfortable, and Affordable Next-Generation Device Available Through an Industry-First Remote Process

Key findings demonstrate value of network solutions to secure and digitalize the pharmaceutical supply chain

Survey results point to people being more cautious with routine, leisure activities - such as traveling, brushing teeth, even playing with grandchildren - due to potential risk of major bleeding

Today, Leo Lens Pharma, an emerging San Diego-based pharmaceutical company focused on helping protect sight, is pleased to announce that its lead asset, LL-BMT1, is ready for IND submission and human clinical evaluation. LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for one week. After a pro

Potential best-in-class profile for an oral sphingosine-1-phosphate receptor modulator - Dose-dependent reduction in circulating lymphocytes - - Rapid lymphocyte recovery after cessation of dosing - - Phase 2 study in ulcerative colitis patients in 4Q 2020 - ENCINITAS, Calif. and CAMBRIDGE, United Kingdom, June 23, 2020 (GLOBE NEWSWIRE) -- Oppilan Pharma, Ltd., a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for the treatment o

Geospark Analytics, the world class leader in developing applied artificial intelligence (AI) solutions for global threat and risk assessment, was just awarded a five-year, multi-million dollar contract with the U.S. Department of Health and Human Services (HHS) for use of the company’s Hyperion platform, its COVID-19 risk model, and development of new AI-driven disease outbreak models.

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com [23-June-2020] TORONTO , June 23, 2020 /PRNewswire/ -- Aleafia Health Inc. (TSX: AH, OTC: ALEAF), a Canadian cannabis health and wellness company, today announced that the Chief Executive Officer, G

MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist, advancing with first-in-human trials expected to initiate in 3Q20 – – Further investment in nevanimibe for congenital adrenal hyperplasia (CAH) not planned following interim data review – – Strategic evaluation in place to determine future corporate strategy – ANN ARBOR, Mich.--( BUSINESS WIRE )-- Millendo Therapeutics, Inc. (Nasdaq: MLND), a biopharmaceutical company pri

Kepley BioSystems has completed patent work surrounding the technology for a novel air sterilization mask, as well as for controlled spaces to directly eliminate airborne viral, bacterial and fungal pathogens.